论文部分内容阅读
给大鼠腹腔注射氯化汞溶液（０．５μｍｏ１Ｈｇ／ｋｇ体重），并同时经口投与０，１ｍｍｏｌ／ｋｇ的ＤＭＰＳ，每天一次，连续５天；或给大鼠腹腔注射氯化汞溶液（２．０μｍｏｌＨｇ／ｋｇ体重），每天一次，连续５天后再经口投与３次０．２ｍｍｏｌ／ｋｇ的ＤＭＰＳ，观察口服ＤＭＰＳ对尿汞和肝肾汞含量以及尿ＡＬＰ和尿ＮＡＧ酶活性的影响。实验结果显示口服ＤＭＰＳ能够促进染汞大鼠的尿汞排泄，降低肝脏、肾皮质的汞含量，减少汞的体负荷。但染汞同时经口投与ＤＭＰＳ，可能会促进汞的肠道再吸收，并引起一过性肝汞含量增高。实验结果未显示ＤＭＰＳ对染汞大鼠的尿酶活性有明显影响，需进一步深入研究。
The rats were intraperitoneally injected with mercuric chloride solution (0.5μmol / kg body weight) and orally administered with 0,1mmol / kg of DMPS once daily for 5 consecutive days or by intraperitoneal injection of mercuric chloride solution (2 .Oμmol Hg / kg body weight) once a day for 5 consecutive days and then orally administered 3 times 0.2mmol / kg of DMPS to observe the effect of oral DMPS on urinary mercury and liver and kidney mercury and urine ALP and urine NAG enzyme activity. The experimental results show that oral administration of DMPS can promote urinary mercury excretion in mercury-stained rats, reduce the mercury content in the liver and renal cortex, and reduce the body burden of mercury. However, simultaneous dosing of mercury with DMPS may promote gut reabsorption of mercury and cause an increase in transient liver mercury levels. The experimental results do not show that DMPS has a significant effect on the urease activity of mercury-stained rats, which needs further study.